Alkermes plc. 8-K

What Happened

• Alkermes plc (ALKS) announced on June 15, 2026 that orphan drug designations were granted for its investigational product alixorexton. The company disclosed the news via a press release and filed an 8-K (Items 7.01 and 8.01) to make the information public under Regulation FD.

Key Details

• Filing date: June 15, 2026.
• Securities filing: Form 8-K, Items 7.01 (Regulation FD Disclosure) and 8.01 (Other Events).
• Related press release: Furnished as Exhibit 99.1 to the 8-K and incorporated by reference.
• Interactive data: Cover page interactive data file included (Exhibit 104).

Why It Matters

• The filing confirms Alkermes made the orphan-designation news public and provided the related press release to the SEC, ensuring equal access to material information for investors. Orphan drug designations are a regulatory milestone for a drug candidate and are commonly viewed as a noteworthy development for a company’s pipeline; the 8-K itself does not detail the specific indications or regulatory jurisdictions for the designations. Investors should review the attached press release (Exhibit 99.1) and any subsequent filings or company communications for more detail on indications, regulatory scope, and potential implications for development plans.